Advance Auto Parts will "beat" earnings this quarter -- but that's not what investors are worried about.Advance Auto Parts (AAP -7.08%) stock tumbled 7.3% through 1 p.m. ET Thursday, leaving investors wondering "what went wrong?"The auto parts retailer preannounced "highlights" from its Q2 earnings today, and the highlight-iest part of all was this: Q2 revenue that Wall Street predicted at $1.97 billion will definitely beat that number, and might rise as high as $2 billion. Advance Auto Parts Q2 earningsSo ...

墨西哥总统辛鲍姆：墨西哥将"很快"公布墨西哥国家石油公司的计划。墨西哥国家石油公司正在解决其 与服务提供商的债务问题。 ...

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is facing significant financial distress, with a total debt of 2.164 billion yuan and overdue debts amounting to 1.81 billion yuan, leading to a serious risk of bankruptcy [1][5]. Group 1: Debt and Financial Status - The company's total debt scale is 2.164 billion yuan, with overdue debts totaling 1.81 billion yuan and litigation-related debts amounting to 1.26 billion yuan [1][5]. - Most of the company's bank accounts, except for those of its subsidiary Ningxia Huahui Environmental Technology Co., Ltd. and its wholly-owned subsidiary Ningxia Tianfu Activated Carbon Co., Ltd., are frozen, severely impacting its liquidity [1][5]. - Although the bank accounts of Zhongke New Materials Co., Ltd. have been unfrozen, the company is currently lacking sufficient funds and liquid assets to repay its debts, indicating a significant risk to its ongoing operations [1][5]. Group 2: Litigation Status - The company is a defendant in multiple lawsuits, including disputes over loan contracts, equity transfer contracts, sales contracts, construction contracts, and securities fraud [2][5]. - A recent court ruling from the Guangdong Zhanjiang Intermediate People's Court dismissed the claims made by Guangdong Nanyue Bank against the company, stating that the bank failed to verify the public disclosure of the guarantee matters [3][5]. - The court supported the company's defense regarding the "maximum pledge contract," ruling that it does not have legal effect, thus not impacting the company's current or future profits [3][5].

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is facing significant financial distress, with a total debt of 2.164 billion yuan and overdue debts amounting to 1.81 billion yuan, leading to severe operational challenges and potential bankruptcy risks [1][5]. Debt and Financial Situation - The company's total debt stands at 2.164 billion yuan, with overdue debts totaling 1.81 billion yuan and litigation-related debts amounting to 1.839 billion yuan [1][5]. - Most of the company's bank accounts, except for those of its subsidiaries, are frozen, severely limiting its liquidity and ability to repay debts [1][5]. - Despite the unfreezing of bank accounts for Zhongke New Materials, the company lacks sufficient funds and liquid assets for debt repayment, indicating a critical risk to its ongoing operations [1][5]. Litigation and Legal Proceedings - The company is currently a defendant in multiple lawsuits, including disputes over loan contracts, equity transfer contracts, sales contracts, construction contracts, and securities fraud [2][5]. - A specific lawsuit regarding a construction contract dispute has resulted in a court ruling, which the company has decided not to appeal [3][5]. - The financial impact of ongoing litigation has been accounted for in the company's audited annual report for 2024, but the exact effects on current and future profits remain uncertain due to the status of various lawsuits [2][3].